Do you see suspension reaching a point soon where the specific productivity is better than adherent systems?
This question is part of the following Ask The Expert session:
Job Title: Head of Technical Operations, Viral and Gene Therapy Manufacturing
I think we’re already there. Our VirusExpress Lentivirus Production platform has been shown to outperform adherent systems (by as much as 5x) with regards to overall titer and specific productivity. Future enhancements such as the optimization of transfection process, the introduction of better transfection reagents, and improved parameters used for the growth of cells, will continue to improve the overall productivity.